Northwestern University scientists have uncovered a hidden molecular "control switch" inside a protein that helps the body ...

CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026Planned milestones include pivotal dose selection, ...

LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

Northwestern University scientists have uncovered a hidden molecular "control switch" inside a protein that helps the body ...

A research team presents an overview of recent advances in the microbial biosynthesis of L-tryptophan (L-Trp) and its structurally diverse derivatives, highlighting how synthetic biology and metabolic ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional ...

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Rezolute, Inc. is downgraded to a Sell after its phase 3 sunRIZE trial for congenital hyperinsulinism failed. Learn more about RZLT stock here.

Northwestern University scientists have uncovered a hidden molecular "control switch" inside a protein that helps the body sense taste, control blood sugar and defend the gut.